Exicure, Adbiotech Co-Develop Burixafor
Analysis based on 7 articles · First reported Apr 22, 2026 · Last updated Apr 23, 2026
The co-development agreement between Exicure and ADBiotech is expected to positively impact the stock prices of both companies due to the potential expansion of Burixafor's therapeutic applications. This collaboration could lead to new treatments for significant diseases, attracting investor interest in the biotechnology sector.
Exicure and ADBiotech have entered into a co-development agreement to explore combination therapies based on Burixafor (GPC-100). The collaboration will focus on evaluating Burixafor in indications such as sickle cell disease, acute myeloid leukemia, and solid tumors. Under the agreement, ADBiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and lead clinical and regulatory strategy. Burixafor previously completed a Phase 2 clinical trial in multiple myeloma. The parties intend to conduct further in vivo validation studies and potentially advance programs into clinical trials, also seeking funding for future development.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard